Featured
Featured posts

0 2055
marijuana_glaucoma

Research has shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30%. Despite the findings from early research, very few ophthalmologists support the use of medical cannabis in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with marijuana is that the potential adverse effects, particularly smoking cannabis, outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, which heightens the risk of permanent vision loss.

Additionally, because its therapeutic effects on glaucoma are short-term, patients would have to consume marijuana frequently; once every three to four hours. Physicians claim that because glaucoma needs to be treated 24 hours per day, patients would need to consume marijuana six to eight times over the course of a day to achieve consistently decreased IOP levels. Such frequency is difficult to maintain and could heighten the risk of developing a marijuana use disorder. However, when it comes to late stage glaucoma, ophthalmologists are more inclined to embrace cannabis as a treatment. At the end stages of glaucoma, it is less about directly targeting the glaucoma and more about alleviating the accompanying symptoms.

Ophthalmologist Andrew Bainnson, MD stated, “We’ve known for some time that medical marijuana is very effective for treating nausea and pain, but not so much for glaucoma. However, there are some patients with end stage pain and nausea who may benefit [from medical marijuana], but not from the glaucoma point of view.” The body’s own internal cannabinoid system, called the endocannabinoid system (ECS), is one of our most important physiological systems. Nearly every aspect of our health including: inflammation, immune response, neuroprotection, pain modulation, are all dependent on the ECS. Given the vital role of the ECS, particularly in neuroprotection and inflammation, many scientists believe the development of cannabinoid-based medications may be useful in treating glaucoma.

1 2636

Cannabis shops and manufacturers have increasing concerns that the Trump Administration will enforce federal laws that restrict farming and selling the drug. This will reverse the president’s stance during his campaign and potentially overturn what has become a $7 billion industry. The worry was provoked by comments from White House spokesman Sean Spicer recently that the government would most likely boost its enforcement of drug laws.

Attorney General Jeff Sessions stated that he is “dubious” about the benefits of marijuana. He said, “Marijuana is against federal law, and that applies in states where they may have repealed their own anti-marijuana laws. So yes, we will enforce law in an appropriate way nationwide. It’s not possible for the federal government, of course, to take over everything the local police used to do in a state that’s legalized it. And I’m not in favor of legalization of marijuana. I think it’s a more dangerous drug than a lot of people realize.”

The comments have sparked worry with Chuck Smith, co-founder of Dixie Brands, a Denver-based company that manufactures topicals and edibles infused with THC, the active ingredient in cannabis. He founded the company in 2010 and now employs more than 100 people across Arizona, Colorado, California, and Nevada. Smith stated, “My concern right now for both the company and industry is just uncertainty. It’s hard to build an industry or a company when you don’t have clarity.”

The administration’s statements affected shares of Innovative Industrial Properties, which invests in cannabis-growing facilities and is one of the few publicly traded cannabis companies. Its stock price plummeted on the day of Spicer’s press conference and are down more than 13% since then. However, two other marijuana stocks, GW Pharmaceuticals and Cara Therapeutics, seem to have not been affected by the news.

Eight states now allow the use of cannabis recreationally, while more than two dozen states have legalized it for medical purposes. Twenty-one states have decriminalized cannabis. A recent Quinnipiac Poll found 71% of voters think the government should not restrict federal drug laws in states where marijuana is legal. Increasing acceptance has led to an jump in the market for cannabis in North America, with sales rising 34% to nearly $7 billion in 2016, according to Arcview Market Research. By 2021, the industry is likely to climb close to $22 billion.

Companies like Dixie Brands are charging that hike. The privately held company would not disclose current numbers, but in 2014 it was valued at $40 million. Smith said, “It’s hard for us to kind of go backwards. President Trump said he was going to allow this to be a state’s rights issue. We took him at his word.” Trump has sent mixed messages on cannabis. In the 1990s, he called for legalizing all drugs. On the campaign trail, he reiterated his support for medical cannabis and his deference to states to pass their own laws regulating the drug.

2 1749

The cannabis industry continues to face threats from Attorney General Jeff Sessions as his campaign against cannabis continued this week.

The AG recently said, “I realize this may be an unfashionable belief in a time of growing tolerance of drug use. But too many lives are at stake to worry about being fashionable. I reject the idea that America will be a better place if marijuana is sold in every corner store. And I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana – so people can trade one life-wrecking dependency for another that’s only slightly less awful. Our nation needs to say clearly once again that using drugs will destroy your life.”

Sessions should take a lesson from Joe Rogan. In a YouTube video, Rogan said, “The only reason why marijuana is illegal is because of economics. If marijuana was legal, it would cost pharmaceutical and alcohol companies billions of dollars every year. The Partnership for a Drug-Free America is funded by alcohol companies. Alcohol is a sanctioned drug”

Marijuana can treat several debilitating diseases and improve the daily life of millions of people around the world.

Ten illnesses that can be treated by marijuana

1.Marijuana can be used to treat and prevent glaucoma. According to the National Eye Institute, marijuana decreases the pressure inside the eye. “Studies in the early 1970s showed that marijuana, when smoked, lowered intraocular pressure (IOP) in people with normal pressure and those with glaucoma.”

2.Marijuana helps reverse the carcinogenic effects of tobacco and improves lung health. In January 2012, a study was published in Journal of the American Medical Association which said marijuana does not impair lung function and it can even increase lung capacity.

3.Marijuana can help control epileptic seizures. Charlotte Figi suffers from Dravet’s Syndrome and a strain of marijuana called “Charlotte’s Web” has decreased Charlotte’s seizures from 300 a week to just one every seven days.

4.Marijuana can decrease anxiety. In 2010, researchers at Harvard Medical School suggested that that some of marijuana’s benefits may be associated with reduced anxiety.

5.THC slows the progression of Alzheimer’s disease. A study led by Kim Janda of the Scripps Research Institute suggests that marijuana may be able to slow the progression of Alzheimer’s disease. In 2006, the study published in the journal of Molecular Pharmaceutics found that THC, the active chemical in marijuana, slows the formation of amyloid plaques by blocking the enzyme in the brain that makes them. These plaques are what kill brain cells and cause Alzheimer’s.

6.Marijuana helps ease the pain associated with multiple sclerosis. GW Pharmaceuticals (GWPH) has developed a drug derived from cannabis called Sativex which helps patients who suffer from multiple sclerosis.

7. Marijuana relieves arthritis discomfort. In 2011, researchers said that marijuana alleviates pain, reduces inflammation and promotes sleep, which may help relieve pain for people suffering from rheumatoid arthritis.

8.Marijuana can potentially eliminate Crohn’s disease. A study in Israel showed that smoking a joint significantly reduced Crohn’s disease symptoms in 10 out of 11 patients. Marijuana caused a complete remission in five of the patients.

9.Marijuana helps veterans suffering from PTSD. The Department of Health and Human Services recently signed off on a proposal to study marijuana’s potential as part of the treatment for veterans with post-traumatic stress disorder.

10.Marijuana reduces some of the pain and nausea from chemotherapy and stimulates appetite.

0 2233

According to a story that appeared a couple of years back in The Philadelphia Inquirer, law enforcement in Pennsylvania were arresting about 21,000 people each year for possession of cannabis, and another 5,500 for growing marijuana. The column by Chris Goldstein, an editor at Freedom Leaf magazine, cited a report from the RAND Corp. think tank that estimated it costs $1,266 for the handling of every basic misdemeanor marijuana arrest.

That number rises to $8,600 for each prosecution of someone accused of growing the plant. Based on those figures, it predicted that Pennsylvania was spending more than $73 million a year on those cases, and that doesn’t include the costs of jail, prison, and supervision of those sentenced to parole and probation. What if Pennsylvania could not only wipe out those costs, but also gain millions from cannabis?

State Auditor General Eugene DePasquale said the state could earn $200 million a year by permitting recreational cannabis use and taxing it. At a recent news conference the auditor general noted that Colorado, with less than half the population of our state, is pulling in about $129 million annually through taxes on the farming and purchase of cannabis. In Washington state, that figure is $220 million.

DePasquale isn’t foolish enough to think such a move would find easy sledding in our Legislature, which has never had a reputation for being particularly visionary — or productive, for that matter. “It is an entirely fair and appropriate question to say, can this ever happen in Pennsylvania?” he said. In fact, it took years of pleas and protests from advocates before the Legislature finally approved use of medical marijuana in 2016, and that option won’t even be available to those who need it until next year, if all goes well.

House Republican spokesman Steve Miskin stated, “We don’t even have the medical cannabis program up and running yet, so it’s clearly a little premature to jump to the next step. While we’re appreciative of the auditor general’s multiple policy thoughts, as Pennsylvania and the nation is facing a serious drug problem, I’m not sure that legalizing a Schedule I narcotic is the best response.”

0 2763

CBD is well-known for its health benefits, especially in treating rare seizure disorders. There are other reasons people try CBD products, also. A neurologist and psychopharmacology researcher, Dr. Ethan Russo, notes in a study that the therapeutic effects of CBD are broad, including: analgesic, anti-inflammatory, antiemetic, antioxidant, anti-psychotic, anti-anxiety, anti-convulsant and cytotoxic in certain cancer cells. Typically, CBD products are primarily made from the concentrated extract of the flowers, leaves and possibly stalks of marijuana or hemp. Most CBD products are either oil-based tinctures or capsules that are consumed orally, or topicals applied to the skin. However, there is a growing variety of other products containing CBD, including those for pets.

To find out if CBD would show on a urine drug test, we consulted employment drug testing expert Barry Sample, who is the director of science and technology for Quest Diagnostics. Sample stated, “If the product contains only CBD and has had the THC removed, then an individual being tested would not be expected to test positive for marijuana or marijuana metabolite.” We contacted cannabis health and science researcher, Paul Armentano. Armentano stated, “Not unless those products also contain quantities of THC. Drug tests screen for either THC or the carboxy-THC metabolite, not for CBD.”

Both experts agree; as long as there is no THC in the CBD products, then a urine test would not test positive for THC. There may be minute amounts of THC in CBD products. An aspect in cannabinoid compounds that aids efficacy is the entourage effect. Coined by venerable Israeli cannabis researcher Raphael Mechoulam in 1999, the entourage effect is the belief that the compounds in marijuana work better together than if the compounds are isolated. CBD products, in addition to the CBD cannabinoid, may contain additional cannabis compounds, including THC, to purportedly increase the effectiveness of the product.

0 1100

Vinergy Resources/MJ BioPharma Develops a Disruptive Solvent Based Extraction System

The project currently underway for an existing customer, utilizes an ethanol / CO2 co-solvent blend and specialized equipment to achieve medicinal products with significantly increased purity. The current iteration of the machine has the physical footprint of a standard shipping skid and incorporates safety and process control systems in one easy to use platform.

Mr. Kent Deuters, CEO on MJ BioPharma said, “This system can produce greater yields and higher quality end product results with less solvent and less time. The process is safe and can be tailored to fit local safety, electrical and workplace laws. The system has been tested to work with other solvent blends and may potentially be capable of producing other useful end products such as terpenes – an area which can add immediate value for the Company.”

The Company will provide more information on the system in the coming weeks. Industry participants are invited to contact the company for further technical data.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Vinergy Resources Ltd.

Glen Macdonald, Director

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

1 3943

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Disclaimer:
Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

1 2906

The marijuana industry is getting ready to take a step forward in its venture for validity and long-term stability. The American Society for Testing and Materials (ASTM International) recently announced that it will put a committee of industry representatives and experts together to create a set of guidelines in six technical areas: Indoor and outdoor horticulture and agriculture, Quality management systems, Laboratory standards, Processing and handling, Security and transportation, Personal training/ assessment and credentialing.

ASTM International’s announcement is welcome news to an industry that operates with no federal oversight. Uniform standards should provide additional assurance to insurance carriers, the medical community, and the federal government as the pathway to full legalization continues. There are definite benefits to the marijuana industry from the creation of published standards, which should assist manufacturers and distributors in establishing baselines for testing and quality control, provide practitioners and dispensaries a standard by which to prescribe and dispense, and allow insurers to better underwrite the risks being covered.

The advancement and stability of the marijuana market stands to improve when insurers are more confident in the ability to use objective risk management metrics through accepted practices and standards for analysis, manufacturing, and transportation of these products. This should encourage more carriers to write policies for the cannabis industry.
Pesticides – Distributors, prescribers, users, and insurers want to be assured their product is free of toxic sprays and treatments.

Contaminates – Distributors, prescribers, users, and insurers need assurance that the products are free of contamination, such as mold, bacteria, yeast, and other microorganisms. There is growing demand from medical cannabis patients for higher-quality packaging that either displays an expiration date or provides greater protection from oxidation and degradation over time.

Potency – Not all marijuana plants, products, and derivatives are the same. They differ in their pharmacology, potency and appearance. They also can be distinguished by variables such as whether they are farmed outdoors or indoors, or grown organically. Distributors, prescribers, users, and insurers need to know that the potency is accurate.
Worker Safety – A 2017 study by New Frontier Data anticipates that marijuana industry hiring will eclipse manufacturing hiring by the year 2020. Inherent in this growth is an increased potential for workplace injuries and the risks related to marijuana businesses and their carriers. The U.S. market needs to know that employees are receiving the necessary training, instruction, education and protection in the cultivation, transporting, packaging, extracting and sales operations. ASTM International is expected to produce standards, ranging from best manufacturing practices to protective equipment and proper ventilation, that address workplace dangers.

Labeling – Every marijuana-legal state currently has, or is drafting, its own labeling requirements. A uniform labeling standard will give distributors, prescribers, and insurers confidence that the product is labeled consistently with a national standard. Quality-Control Testing – Ensuring a relatively uniform method of testing from state to state, and facility to facility, should improve product quality and consistency, and reduce the exposure from product liability and contamination claims along with the potential for product recalls. Reliably consistent testing also will allow patient-users to evaluate levels of all known useful cannabinoids, including levels of THC, CBD, and CBN, to help them choose strains or products better suited to their needs.

Twenty-eight states have regulated or decriminalized marijuana and/or its derivatives. The marijuana market cannot reach its full potential, however, without widespread acceptance from the medical community and the insurance industry. As Corey Tobin of Bolton & Company, a full-service insurance brokerage, explains, “Insurers usually move slowly, although ASTM International’s creation of a set of standards will help the insurers get a better understanding of the needs of these corporations.” While drawing up and examining the guidelines will take time, the design of uniform standards will be an important step forward for the industry in terms of its its long-term stability and validity.

0 1607

Physicians will not prescribe marijuana to treat autism in children because no information exists to support such a course of therapy . However, the research does not exist because of medical establishment worries about marijuana testing, with its many active compounds seen as conceivably uncontrollable variables, on children. In the absence of practical information, however, is a growing body of anecdotal proof that marijuana is making autistic children healthier and happier. Some physicians are listening.

Doctor Daniele Piomelli, one of the world’s top neuroscientists and endocannabinoid researchers stated, “Anecdotes should not be dismissed.” The University of California-Irvine faculty member will not consider prescribing marijuana at this time, but is aware of the increasing desire for it. Piomelli continued, “An anecdote is a pointer. It’s something that suggests something needs to be either proven or disproven.”

One scientist attempting to do just that is Doctor Giovanni Martinez, a clinical psychologist in Puerto Rico. His alternative treatment includes his creation of SURF4DEM, a foundation that introduces children and families affected by autism to the therapeutic benefits of surfing. Martinez is studying the therapeutic possibilities of treating children who have autism with CBD oil, and reports positive results. He recounted one particular case in which a child he treated spoke his first words after receiving a twice-daily spray of hemp oil. After three weeks, the child went from being non-verbal to developing considerable language skills.

Martinez stated, “initially the child would become so frustrated with his inability to communicate, he would would act out and injure himself. But, now that he can express himself, he laughs and enjoys life.” Martinez continued, “It’s incredible to see a child go from being non-communicative to achieving a significant improvement in quality of life, for both the child and his family.”

1 1719

Future Farm Subsidiary to Manage Cannabis Cultivation Facility

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB:FFRMF) is pleased to announce that its majority owned subsidiary, FFM Consulting Services, LLC, a California limited liability company, has entered into a management agreement with a California non-profit company. The non-profit has secured a sublease for the purpose of cultivating premium grade cannabis in Riverside County, California. The cultivation facility will supply its high-quality cannabis to the previously announced extraction facility where it will be further processed into premium grade concentrates.

The Company expects to help the non-profit operate and expand within the 17,000-square foot state-of-the-art cultivation facility and that it will be fully functional following completion of facility modifications within three months, with the first harvest 90-days thereafter. The cultivation operation will implement the use of Future Farm’s CEA systems, including the Company’s patented vertical farming technology and COB LED grow lights, thereby positioning the non-profit to be able to produce high-grade and pure cannabis ideally suited for extraction. By using Future Farm’s proprietary vertical stacking technology for its clones, there will be more space to devote to the flowering room, which will increase the overall cannabis production capacity in the space.

California is the 6th largest economy in the world and according to ArcView Research the cannabis market in California is expected to reach US$6.5 billion by 2020.

“We’re thrilled to have reached another major milestone for our emerging company and excited to have the opportunity to manage this cultivation facility as it allows us to showcase our ability to expertly manage the production of consistent high-grade cannabis,” said Bill Gildea, CEO of Future Farm Technologies.

“This cultivation operation provides us with an important strategic advantage to control our supply of locally grown, high-grade raw material for our extraction operations and at the same time incorporate the use of Future Farm’s diversity of equipment, including vertical farming technologies and COB LED lighting solutions,” commented John Sweeney, COO of Future Farm Technologies.

About Future Farm

The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

FUTURE FARM TECHNOLOGIES INC.
#5-9079 Shaughnessy Street
Vancouver BC
V6P 6R9

For further information, contact:
William Gildea
Director
617.834.9467

On behalf of the Board
Future Farm Technologies Inc.
William Gildea
CEO & Chairman

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements